Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To study GC1126A in patients with Thrombotic Thrombocytopenic Purpura (TTP)

Next Previous
Trial Profile

To study GC1126A in patients with Thrombotic Thrombocytopenic Purpura (TTP)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GC 1126A (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions

Most Recent Events

  • 10 Oct 2023 New trial record
  • 05 Oct 2023 According to a GC Biopharma Media release, GC1126A has received an Orphan Drug Designation for the treatment of Thrombotic Thrombocytopenic Purpura (TTP), on September 27 from the U.S. Food and Drug Administration (FDA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top